SX-004 (Gloria Pharmaceuticals)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameSX-004 (Gloria Pharmaceuticals)
Drug Alias Namemeditinib
ClassificationSmall molecules
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase SRC inhibitorsAnticancer protein kinase inhibitors
TargetsTyrosine-protein kinase SRCBcr-Abl tyrosine kinase
Therapy Area/IndicationsSolid tumoursLeukemia, Myelogenous, ChronicLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Medesignpharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHarbin Gloria Pharmaceuticals Co Ltd
Inactive CompaniesBeijing Medesignpharma Co Ltd
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsSolid tumoursLeukemia

Other Information

ATC CodeN/A
Related LinksN/A